CN1616069A - A ginkgo medicinal composition, its preparation method and its use - Google Patents
A ginkgo medicinal composition, its preparation method and its use Download PDFInfo
- Publication number
- CN1616069A CN1616069A CN 200410083882 CN200410083882A CN1616069A CN 1616069 A CN1616069 A CN 1616069A CN 200410083882 CN200410083882 CN 200410083882 CN 200410083882 A CN200410083882 A CN 200410083882A CN 1616069 A CN1616069 A CN 1616069A
- Authority
- CN
- China
- Prior art keywords
- ginkgo
- extract
- pharmaceutical composition
- preparation
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims description 124
- 241000218628 Ginkgo Species 0.000 title claims description 119
- 235000011201 Ginkgo Nutrition 0.000 title claims description 119
- 239000000284 extract Substances 0.000 claims abstract description 68
- KWWLGXNRLABSMP-UHFFFAOYSA-N phosphoric acid;2,3,5,6-tetramethylpyrazine Chemical compound OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C KWWLGXNRLABSMP-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000003814 drug Substances 0.000 claims abstract description 36
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 9
- 230000002490 cerebral effect Effects 0.000 claims abstract description 9
- 230000000302 ischemic effect Effects 0.000 claims abstract description 9
- 230000004089 microcirculation Effects 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims description 51
- 238000002347 injection Methods 0.000 claims description 34
- 239000007924 injection Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000011347 resin Substances 0.000 claims description 25
- 229920005989 resin Polymers 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 206010008088 Cerebral artery embolism Diseases 0.000 claims description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 5
- 201000010849 intracranial embolism Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000029078 coronary artery disease Diseases 0.000 claims description 4
- -1 filter Substances 0.000 claims description 4
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000009429 Ginkgo biloba extract Substances 0.000 claims 11
- 229940068052 ginkgo biloba extract Drugs 0.000 claims 7
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims 7
- 229930003935 flavonoid Natural products 0.000 claims 4
- 150000002215 flavonoids Chemical class 0.000 claims 4
- 235000017173 flavonoids Nutrition 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 229910021536 Zeolite Inorganic materials 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000010457 zeolite Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 208000007536 Thrombosis Diseases 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 230000000916 dilatatory effect Effects 0.000 abstract description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 2
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 description 43
- 235000011949 flavones Nutrition 0.000 description 43
- 150000002213 flavones Chemical class 0.000 description 41
- 229940090044 injection Drugs 0.000 description 24
- 238000011282 treatment Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical group C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 230000001476 alcoholic effect Effects 0.000 description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 7
- MOLPUWBMSBJXER-YDGSQGCISA-N bilobalide Chemical compound O([C@H]1OC2=O)C(=O)[C@H](O)[C@@]11[C@@](C(C)(C)C)(O)C[C@H]3[C@@]21CC(=O)O3 MOLPUWBMSBJXER-YDGSQGCISA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 239000013558 reference substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 4
- 235000008800 isorhamnetin Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000005875 quercetin Nutrition 0.000 description 4
- 229960001285 quercetin Drugs 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 229910052665 sodalite Inorganic materials 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000005098 blood-cerebrospinal fluid barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940093181 glucose injection Drugs 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 235000008777 kaempferol Nutrition 0.000 description 3
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000001738 Nervous System Trauma Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 208000028412 nervous system injury Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical class [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- RQKFOGXUTRDQPB-UHFFFAOYSA-N hydron;2,3,5,6-tetramethylpyrazine;chloride Chemical compound Cl.CC1=NC(C)=C(C)N=C1C RQKFOGXUTRDQPB-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000010068 shuxuening Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The gingko medicine composition consists of gingko leaf extract and ligustrazine phosphate in the amount of 1-100 times of gingko leaf extract. The preparation process of the medicine composition is also disclosed. As the compound preparation, the medicine composition of the present invention has the complementary and synergistic effects of gingko leaf extract and ligustrazine phosphate, including promoting blood circulation to disperse blood clots, resisting platelet aggregation, dilating blood vessel and improving microcirculation, and may be used in preparing medicine for ischemic cardiac and cerebral vascular diseases.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, Its Preparation Method And Use, specifically, relate to a kind of pharmaceutical composition that combines by ligustrazine phosphate and the Folium Ginkgo extract that from Folium Ginkgo, extracts, its preparation method and the application aspect preparation treatment ischemic cardio cerebrovascular diseases medicine thereof.
Background technology
Contain active ingredients such as total flavones, total lactone in the Folium Ginkgo extract, total flavones is the main active of Folium Ginkgo extract.The content of total flavones in Folium Ginkgo is 0.5%～1% (W/W), mainly exists with the glycoside form, and main glycoside unit is Quercetin, kaempferol and isorhamnetin.The contained Ginkgo total flavones of Folium Ginkgo extract has dilating coronary blood vessel, cerebrovascular, blood circulation promoting and blood stasis dispelling, improves symptom and memory function that cerebral ischemia produces.Folium Ginkgo extract all has improvement to cerebral thrombus patient's cerebral circulation, glucose metabolism, breathing, and functional central nervous system injury is had therapeutical effect.The clinical ischemic cardio cerebrovascular diseases that is usually used in of Folium Ginkgo extract, angina pectoris, cerebral embolism, cerebral vasospasm etc.
Ligustrazine phosphate is 2 phosphate monohydrate (C
8H
12N
2H
3PO
4H
2O),, have antiplatelet aggregative activity, and accumulative platelet is had depolymerisation, expansion small artery, microcirculation improvement, cerebral blood flow increasing and function of promoting blood circulation to disperse blood clots for white or off-white color crystalline powder.Ligustrazine phosphate absorbs and drains rapidly, can pass through blood-CSF barrier.The clinical ischemic cerebrovascular (as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism) that is used for.
99100263.6 disclose a kind of pharmaceutical composition for the treatment of cerebrovascular, this pharmaceutical composition contains ligustrazine hydrochloride 15～30%, Radix Notoginseng total arasaponins 40～60%, Semen Ginkgo extrac 15～40%.This pharmaceutical composition proves a kind of action temperature and persistent medicine through pharmacology, toxicological experiment, can strengthen anti-stress and endurance, can effectively prevent the formation of tampon, promotes the meninges microcirculation, blood flow increasing, and the control local cerebral ischemia improves motor behavior.
But at present, after still no-trump Folium Ginkgo extract and ligustrazine phosphate carry out assembly with certain proportion, make the report that medicine carries out clinical use.
Summary of the invention
The object of the present invention is to provide a kind of ginkgo medicine composition, said composition is the compound preparation that Folium Ginkgo extract and ligustrazine phosphate form by the special ratios assembly.
Another object of the present invention is to provide a kind of preparation method of ginkgo medicine composition.
A further object of the present invention is to provide a kind of preparation treatment ischemic cardio cerebrovascular diseases, as the application of cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vasospasm, brain insufficiency, alzheimer disease, parkinson, apoplexy, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris, each disease medicament aspect of myocardial infarction.
Another purpose of the present invention is to provide a kind of prepare the microcirculation pathological changes that treatment hepatic fibrosis, diabetes cause, the application of each disease medicament aspect of vasculitis.
Contain ligustrazine phosphate (C in the ginkgo medicine composition of the present invention
8H
12N
2H
3PO
4H
2O) and the Folium Ginkgo extract that from Folium Ginkgo, extracts (in Ginkgo total flavones), contained ligustrazine phosphate weight is 1～100 times of Folium Ginkgo extract (in Ginkgo total flavones) weight in the pharmaceutical composition.
Further, in the ginkgo medicine composition of the present invention ligustrazine phosphate weight be Folium Ginkgo extract (in Ginkgo total flavones) weight preferably be 5～50 times, more preferably 5～20 times, most preferred is 10 times.
Weight portion of the present invention can be the known content units of field of medicaments such as μ g, mg, g, kg.
Ginkgo medicine composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, therefore can use said composition also can contain one or more adjuvant; Such as sodium chloride, starch, Pulvis Talci and magnesium stearate etc., the acceptable adjuvant of pharmaceutical field.
Ligustrazine phosphate of the present invention can adopt the raw material that meets medicinal standard.
Described Folium Ginkgo extract is that the dried leaves of Ginkgoaceae plant Ginkgo biloba is prepared from through extraction.
The preparation method of ginkgo medicine composition of the present invention is: earlier Folium Ginkgo is extracted, the Folium Ginkgo alcohol reflux, the extracting solution thickening filtration, resin absorption, eluting, reconcentration is drying to obtain Folium Ginkgo extract, then Folium Ginkgo extract and ligustrazine phosphate is carried out proportioning and mixes, and adds the compositions that pharmaceutically acceptable adjuvant is made acceptable various dosage forms on the pharmaceutics again.
Specifically, the Folium Ginkgo extract preparation process is:
After Folium Ginkgo is pulverized, adds 8～12 times and measure 60～75% ethanol, twice of 40～50 ℃ of reflux, extract,, each 2～5 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/12, the water that adds 1～2 times of concentrated liquid measure, the reuse addition is that 1～2% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 60～75% alcoholic solution desorbings, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
Its preparation process is preferably: after Folium Ginkgo is pulverized, adds 8～12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 2～4 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8～1/10, the water that adds 1 times of concentrated liquid measure, the reuse addition is that 1% filter aid that concentrates liquid measure filters, and filtrate is through macroporous resin adsorption, and with 70% alcoholic solution desorbing, stripping liquid is evaporated to dried, and the Folium Ginkgo extract that must contain total flavones is standby.
Described filter aid can be sodalite or Pulvis Talci.
Described macroporous resin can be D101 type resin or HP-20 type resin.
During desorbing, the addition of used alcoholic solution is 2～3 times of adsorbent resin amount.
Certainly, in the preparation process of ginkgo medicine composition of the present invention, also can directly adopt the commercially available Folium Ginkgo extract that meets the national drug standards.
Ginkgo medicine composition of the present invention can be prepared into the available dosage form on the various pharmaceuticss, and as lyophilized injectable powder, tablet, capsule, small-volume injection, bulk capacity injection, preferred dosage form is small-volume injection, bulk capacity injection.The various dosage forms of ginkgo medicine composition of the present invention can be according to the conventional production method preparation of pharmaceutical field.Such as using ligustrazine phosphate, Folium Ginkgo extract to mix, be made into required dosage form then with one or more carriers.
Ginkgo medicine composition of the present invention needs to add an amount of sodium chloride as isoosmotic adjusting agent when being prepared into bulk capacity injection.
Research worker of the present invention is tested discovery in a large number, ligustrazine phosphate (C in ginkgo medicine composition
8H
12N
2H
3PO
4H
2Synergism was best when O) weight was 10 times of proportionings of Folium Ginkgo extract (in Ginkgo total flavones) weight, curative effect is best.
The present invention most preferably specification of ginkgo medicine composition bulk capacity injection is the 250ml/ bottle, and every bottle contains ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg.
Usage is as follows: intravenous drip, one time one bottle, 10～15 days is a course of treatment.
Ginkgo medicine composition of the present invention replenishes synergism mutually by Folium Ginkgo extract and ligustrazine phosphate, can play beyond thought effect.Contain effective ingredient such as Ginkgo total flavones, Ginkgo total lactones in the Folium Ginkgo extract of the present invention.Ginkgo total flavones has obvious blood fat reducing, cholesterol reducing effect, increase the coronary blood liquid measure, reduce myocardial oxygen consumption, microcirculation improvement, have and improve symptom and the memory function that cerebral ischemia produces, cerebral circulation, glucose metabolism, breathing to the cerebral thrombosis person all have improvement, and functional central nervous system injury is had therapeutical effect.Bilobalide has anticoagulation, reduces blood viscosity, improves blood flowing characteristic, prevents thrombosis, promotes thrombolytic effect.Ligustrazine phosphate has antiplatelet aggregative activity, and accumulative platelet is had depolymerisation, can expand small artery, and microcirculation improvement, cerebral blood flow increasing and function of promoting blood circulation to disperse blood clots are arranged.Ligustrazine phosphate absorbs and drains rapidly, can play a role by blood-CSF barrier.
Ginkgo medicine composition of the present invention is the compound preparation that Folium Ginkgo extract and ligustrazine phosphate form by the special ratios assembly, and its absorption and drainage can be passed through blood-cerebrospinal fluid barrier rapidly.By the two additional mutually body that acts synergistically on, give full play to blood circulation promoting and blood stasis dispelling, anti-platelet aggregation is arranged, blood vessel dilating, the microcirculation improvement effect, the smelting that is applicable to ischemic cardio cerebrovascular diseases is treated, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism, cerebral vasospasm, brain insufficiency, alzheimer disease, parkinson, apoplexy, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris, myocardial infarction.Also can be used for the microcirculation pathological changes that hepatic fibrosis, diabetes cause, vasculitis etc.
The specific embodiment
Further describe the present invention with embodiment below, help understanding, but described embodiment only is used to illustrate the present invention rather than restriction the present invention the present invention and advantage thereof, better effects if.
Embodiment 1
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/10, the water that adds the equivalent concentrated solution, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 70% alcoholic solution desorbing of 2 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 16g (containing total flavones 4g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 40g can be made into the 100000ml medicinal liquid, finally makes 400 bottles of bulk capacity injections (specification is the 250ml/ bottle).In dense preparing tank, add an amount of 85 ℃ of waters for injection, in dense preparing tank, drop into 900g sodium chloride, fully stir and make dissolving fully, add active carbon by 0.04% of preparation cumulative volume, heat 90 ℃, be incubated 20 minutes, be cooled to 50 ℃, the medicinal liquid decarbonization filtering to dilute preparing tank, is added ligustrazine phosphate and Folium Ginkgo extract in dilute preparing tank, fully stir and make dissolving fully, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, and added water for injection to the dosing amount, transferring PH is 4.8 ± 0.2, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, and embedding is filled nitrogen by bottle during embedding in infusion bottle, sterilization promptly gets infusion products.
Embodiment 2
After Folium Ginkgo 5000g pulverizes, add 10 times of amount 65% ethanol, twice of 45 ℃ of reflux, extract,, each 4 hours, merge extractive liquid,, filter, be evaporated to extracting liquid volume 1/8, the water that adds 1.5 times of concentrated liquid measures, add the 2% Pulvis Talci filter aid that concentrates liquid measure and filter, filtrate is with macroporous resin (as HP-20 type resin) absorption, with 72% alcoholic solution desorbing of 3 times of amounts of macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 50g can be made into the 2000ml medicinal liquid, finally makes 1000 of small-volume injections.In preparing tank, add an amount of 48 ℃ of waters for injection, add ligustrazine phosphate and Folium Ginkgo extract again, fully stir and make dissolving fully, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, and added water for injection to the dosing amount, transferring PH is 4.5, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, and embedding is in ampoule, and ampoule fills nitrogen by propping up during embedding, sterilization promptly gets small-volume injection.
Embodiment 3
After Folium Ginkgo 5000g pulverizes, adds 10 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/9, add 2 times of concentrated solution water gagings, add the 1.5% Pulvis Talci filter aid that concentrates liquid measure and filter, filtrate is with macroporous resin (as D101 type resin) absorption, with 70% alcoholic solution desorbing of 2 times of amounts of macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 200g can be made into the 1000ml medicinal liquid, finally makes 1000 of small-volume injections.Add an amount of 48 ± 2 ℃ of waters for injection in preparing tank, add ligustrazine phosphate and Folium Ginkgo extract again, fully stirring is dissolved it fully, add the Dextran 40 excipient, add active carbon by 0.02% of preparation cumulative volume, left standstill 20 minutes, add water for injection to the dosing amount, transferring PH is 4.8, with the medicinal liquid decarbonization filtering, medicinal liquid is again through end-filtration, medicinal liquid fill behind end-filtration (loading amount 1.0ml/ props up), the freeze-dried powder product is made in lyophilizing behind the false add plug.
Embodiment 4
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 70% ethanol, twice of 50 ℃ of reflux, extract,, each 3 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/8, the water that adds the equivalent concentrated solution, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 70% alcoholic solution desorbing of 3 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 100g can finally make 1000 in tablet.Will Folium Ginkgo extract, ligustrazine phosphate mixes with 80 gram starch mixings after granulate with starch slurry, cross 20 mesh sieve granulate, drying adds 1 gram magnesium stearate compacting in flakes, promptly gets the ginkgo medicine composition tablet.
Embodiment 5
After Folium Ginkgo 5000g pulverizes, adds 12 times and measure 60% ethanol, twice of 50 ℃ of reflux, extract,, each 2 hours, merge extractive liquid, filters, and is evaporated to extracting liquid volume 1/11, the water that adds 2 times of concentrated liquid measures, add the 1% sodalite filter aid that concentrates liquid measure and filter, filtrate is used D101 type macroporous resin adsorption, 65% alcoholic solution desorbing of 3 times of amounts of reuse macroporous resin, stripping liquid is evaporated to dried, 150g to contain the Folium Ginkgo extract of total flavones (containing total flavones 25%) standby.
Take by weighing Folium Ginkgo extract 8g (containing total flavones 2g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 2g can finally make capsule.Behind Folium Ginkgo extract, ligustrazine phosphate and 80 gram starch, 80 gram Pulvis Talci mixings, cross 100 mesh sieves, encapsulated, get the ginkgo medicine composition capsule.
Embodiment 6
The extraction process of Folium Ginkgo extract is with embodiment 1, and different is Folium Ginkgo extract 16g (containing total flavones 4g), ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) 20g.
Experimental example 1
(every bottle contains ligustrazine phosphate (C to this experimental example for the most preferred ginkgo medicine composition bulk capacity injection of the present invention
8H
12N
2H
3PO
4H
2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) detection of injection inspection item of appearance character, pH value, heavy metal and other regulation.
√ character this product is that little yellow is to lurid clear liquid.
√ pH value pH value should be 3.5-5.5 (two appendix VI of Chinese Pharmacopoeia version in 2000).
√ heavy metal precision is measured this product 25ml, puts in the crucible, and water bath method is checked (two appendix VIII of Chinese Pharmacopoeia version in 2000 H, second method) in accordance with the law, contains heavy metal and must not cross 5/1000000ths.
The √ pyrogen: get this product, check (two appendix XI of Chinese Pharmacopoeia version in 2000 D) in accordance with the law, dosage is slowly injected 10ml by the every 1kg of rabbit body weight, should be up to specification.
√ other: should meet under the injection item relevant every regulation (2000 editions two appendix IB of Chinese Pharmacopoeia).
Experimental example 2
(every bottle contains ligustrazine phosphate (C to this experimental example for of the present invention most preferred ginkgo medicine composition bulk capacity injection
8H
12N
2H
3PO
4H
2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) in the qualitative determination of key component.
Get this product 2ml, add 2 of bismuth potassium iodides, promptly generate salmon precipitation.
In the chromatogram that writes down under Ginkgo total flavones and ligustrazine phosphate assay item, the retention time at test sample peak should be consistent with the corresponding peak of reference substance retention time.
This product shows sodium salt and muriatic identification (two appendix III of Chinese Pharmacopoeia version in 2000).
More than 3 kinds of experiments be the qualitative reactions of the contained component of ginkgo medicine composition of the present invention, illustrate and contain definite component in the ginkgo medicine composition of the present invention.
Experimental example 3
(every bottle contains ligustrazine phosphate (C to this experimental example for the most preferred ginkgo medicine composition bulk capacity injection of the present invention
8H
12N
2H
3PO
4H
2O) 100mg, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) in the detection by quantitative of component.Every ml contains the Semen Ginkgo total flavones and should be 36-44 μ g, ligustrazine phosphate (C
8H
12N
2H
3PO
4H
2O) should be 0.36-0.44mg.
Ginkgo total flavones alcohol glycoside (Ginkgo total flavones) assay is measured according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; With methanol-0.4% phosphoric acid (55: 45) is mobile phase; The detection wavelength is 368nm.Number of theoretical plate calculates by the Quercetin peak should be not less than 2500, and separating degree presses Quercetin and the isorhamnetin peak calculates, should be greater than 1.5.
The preparation precision of reference substance solution takes by weighing through the exsiccant Quercetin of phosphorus pentoxide, kaempferol and isorhamnetin reference substance, adds methanol and makes the mixed solution that every 1ml contains 0.03mg, 0.03mg, 0.02mg, in contrast product solution.
The preparation precision of need testing solution is measured this product 100ml, 50 ℃ are evaporated to about 5ml, add methanol 8ml, 18% hydrochloric acid 3ml, put in the water-bath reflux 1.5 hours, and be cooled to room temperature rapidly, move in the 25ml measuring bottle, add methanol and be diluted to scale, shake up, filter through filter membrane (aperture must not greater than 0.45 μ m), as need testing solution.
Accurate respectively reference substance solution and each the 20 μ l of need testing solution of drawing of algoscopy inject high performance liquid chromatograph, measure, and calculate the content of three kinds of glycosides millions respectively, are converted into the content of total flavones alcohol glycoside with following formula.
Total flavones alcohol salidroside content=(quercetin content+kaempferol content+isorhamnetin content) * 2.51
The ligustrazine phosphate assay is measured according to high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2000).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; With methanol-water (50: 50) is mobile phase; The detection wavelength is 295nm.Number of theoretical plate calculates by the ligustrazine phosphate peak should be not less than 2000.
Algoscopy is got this product, adds the mobile phase dissolving and is diluted to the solution that contains 20 μ g among every 1ml, gets 20 μ l and injects chromatograph of liquid, the record chromatogram; It is an amount of that other gets the ligustrazine phosphate reference substance, measures with method, presses external standard method with calculated by peak area.
By three batches of mensuration, every ml content results sees Table 1:
Table 1
| Lot number | Ginkgo total flavones (μ g) | Ligustrazine phosphate (mg) |
| ????20030701 | ?39.0 | ??0.41 |
| ????20030702 | ?38.2 | ??0.38 |
| ????20030703 | ?39.2 | ??0.39 |
Comparative example 1
This example is that (every bottle contains ligustrazine phosphate (C8H12N2H3PO4H2O) 100mg to the most preferred pharmaceutical composition bulk capacity injection of the present invention, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) with separately with YINXINGYE ZHUSHEYE or ligustrazine phosphate injection clinical comparison at treatment ischemic cerebrovascular cerebral infarction, the good efficacy of pharmaceutical composition of the present invention is described, promptly the coordinating effect of ligustrazine phosphate and Folium Ginkgo extract is better than using separately YINXINGYE ZHUSHEYE or ligustrazine phosphate injection.
Matched group 1:32 example, wherein the male is 21 examples, the women is 11 examples.Age 43-72 year, average 57.5 years old.
Matched group 2:32 example, wherein the male is 20 examples, the women is 12 examples.Age 40-70 year, average 56.5 years old.
The ischemic cerebrovascular diagnostic criteria that the equal national cerebrovascular academic conference of all cases is worked out is all made a definite diagnosis through brain CT.
Therapeutic Method:
The most preferred pharmaceutical composition bulk capacity injection of the equal intravenous drip the present invention of treatment group patient injection, one time one bottle, 1 time on the one, treated for 3 weeks;
Matched group 1 patient dilutes YINXINGYE ZHUSHEYE 5ml (containing Semen Ginkgo total flavones 4.2mg and bilobalide 0.3mg) with 5% glucose injection 250ml, and intravenous drip once-a-day, treated for 3 weeks.
Matched group 2 patients dilute ligustrazine phosphate injection 100mg with 5% glucose injection 250ml, and intravenous drip once-a-day, treated for 3 weeks.
In therapeutic process, all look the state of an illness and need give dehydrant, antibiotic for three groups, keep corresponding treatments such as water-electrolyte balance.
Efficacy determination:
Produce effects: symptom and sign disappears substantially or is clearly better, and paralysed limb muscular strength improves more than 2 grades; Effectively: symptom and sign takes a turn for the better, and paralysed limb muscular strength improves 2 grades of less thaies; Invalid: symptom and sign does not have change or increases the weight of.
Therapeutic outcome:
The effective percentage and the curative effect of treatment group and matched group are compared, and two groups of effective percentage of treatment group and matched group are P＜0.01 relatively, and difference has significance, and matched group 1 is not remarkable with matched group 2 differences, the results are shown in Table 2.
Table 2 treatment group and matched group curative effect are relatively
Matched group 1 (n=32) matched group 2 (n=32) treatment group (n=32)
Example numerical example numerical example number
Produce effects 13 13 23
Effective 12 13 8
Invalid 761
Effective percentage 78.1 81.3 96.9
Annotate: two groups of curative effects compare p＜0.01
Comparative example 2
This example is that (every bottle contains ligustrazine phosphate (C8H12N2H3PO4H2O) 100mg to the most preferred pharmaceutical composition bulk capacity injection of the present invention, Folium Ginkgo extract (in Ginkgo total flavones) 10mg, 2.25g sodium chloride) with the clinical efficacy contrast of YINXINGYE ZHUSHEYE at the treatment angina pectoris, the good efficacy of pharmaceutical composition of the present invention is described, promptly the coordinating effect of ligustrazine phosphate and Folium Ginkgo extract is better than using separately YINXINGYE ZHUSHEYE (SHUXUENING ZHUSHEYE).
Clinical settings: coronary heart disease with qi deficiency and blood stasis patient with angina pectoris Patients with Cerebral Infarction 90 examples are divided into treatment group and matched group at random.
60 examples are organized in treatment, male 34 examples, women 26 examples, 40～72 years old age, average 58 years old;
Matched group 30 examples, wherein the male is 21 examples, the women is 9 examples.Age 39-68 year, average 55.3 years old.
All cases all meet national internal medicine meeting cardiovascular special interest group angina pectoris diagnostic criteria and Chinese medical discrimination syndrome of deficiency of heart qi and blood stasis type standard.
Therapeutic Method:
The most preferred pharmaceutical composition bulk capacity injection of the equal intravenous drip the present invention of treatment group patient injection, one time one bottle, 1 time on the one, treated 20 days;
The matched group patient dilutes YINXINGYE ZHUSHEYE 5ml (containing Semen Ginkgo total flavones 4.2mg and bilobalide 0.3mg) with 5% glucose injection 250ml, and intravenous drip once-a-day, was treated 20 days.
Efficacy determination:
Produce effects: transference cure or basic the disappearance, electrocardiogram recovers normally or is roughly normal; Effectively: the angina pectoris attacks number of times obviously reduces, and degree obviously alleviates, and the persistent period obviously shortens, and ECG ST section reduces, more than rise 0.5mv after the treatment, the negative T wave that mainly leads shoal (reaching more than 25%) or by smooth for upright; Invalid: symptom and electrocardiogram do not have change.
Therapeutic outcome:
Treatment group produce effects 34 examples, effective 22 examples, invalid 4 examples, total effective rate is 93.33%; Matched group produce effects 10 examples, effective 13 examples, invalid 7 examples, total effective rate 76.66%.Two groups of total effective rates compare, and difference has significance meaning (P＜0.05).The electrocardiogram total effective rate: treatment group 60%, matched group does not relatively have significance meaning P＞0.05 for 53.33%, two group).Hemorheology: treatment group treatment back whole blood viscosity, plasma viscosity, packed cell volume, the every index of Fibrinogen all obviously descend, and the every index of matched group all also has certain decline, and two groups of comparing differences have significance meaning (P＜0.05).
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100838829A CN1320890C (en) | 2003-10-28 | 2004-10-21 | Ginkgo medicine composition, its preparing method and its use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200310102229.8 | 2003-10-28 | ||
| CN200310102229 | 2003-10-28 | ||
| CNB2004100838829A CN1320890C (en) | 2003-10-28 | 2004-10-21 | Ginkgo medicine composition, its preparing method and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1616069A true CN1616069A (en) | 2005-05-18 |
| CN1320890C CN1320890C (en) | 2007-06-13 |
Family
ID=34796275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100838829A Expired - Lifetime CN1320890C (en) | 2003-10-28 | 2004-10-21 | Ginkgo medicine composition, its preparing method and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1320890C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367963C (en) * | 2005-10-28 | 2008-02-13 | 阿尔贝拉医药(中国)有限公司 | Medicinal composition containing bilobalide B and its preparation process and usage |
| CN103833650A (en) * | 2013-12-12 | 2014-06-04 | 吉林长舜制药有限公司 | Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1262103A (en) * | 1999-01-26 | 2000-08-09 | 山东绿叶制药股份有限公司 | Chinese-medicinal compound extract for curing cerebrovascular diseases |
-
2004
- 2004-10-21 CN CNB2004100838829A patent/CN1320890C/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100367963C (en) * | 2005-10-28 | 2008-02-13 | 阿尔贝拉医药(中国)有限公司 | Medicinal composition containing bilobalide B and its preparation process and usage |
| CN103833650A (en) * | 2013-12-12 | 2014-06-04 | 吉林长舜制药有限公司 | Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient |
| CN103833650B (en) * | 2013-12-12 | 2015-02-25 | 吉林长舜制药有限公司 | Ligustrazine phosphate compound and medicine composition containing the ligustrazine compound and gingko leaf effective ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1320890C (en) | 2007-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038701A (en) | Anti-depression application of albiflorin | |
| CN101485666B (en) | Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor | |
| CN1911257A (en) | Extractive of ginkgo tree leaves, prepn. method and application thereof | |
| CN1384090A (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN1616069A (en) | A ginkgo medicinal composition, its preparation method and its use | |
| CN1278433A (en) | Thrombolytic medicine and its preparation and use | |
| CN1562186A (en) | Preparation of Chinese traditional medicine for curing Illness of Cardiac cerebral ischemia and preparation method | |
| CN1272026C (en) | Medicinal composition for treating cardiocerebral vasculr disease and its preparing method | |
| CN100404039C (en) | A kind of safflower pharmaceutical composition, its preparation method and its application | |
| CN1277831C (en) | Composition of ginkgo internal ester B and its preparation and use thereof | |
| CN100367963C (en) | Medicinal composition containing bilobalide B and its preparation process and usage | |
| CN1712411A (en) | Compound salt of glycyrrhizin and kurarinol, its production and use | |
| CN103626709A (en) | Ligustrazine phosphate compound and drug composition containing ligustrazine phosphate compound and ginkgo leaf effective ingredients | |
| CN101628003A (en) | Extract of ginkgo biloba leaves and dipyridamole composite and preparation method and application thereof | |
| CN100441195C (en) | Medicinal composition containing safflower total flavone and its preparation process and usage | |
| CN1177603C (en) | Gingko leaf slow-releasing table and preparation process thereof | |
| CN1785216A (en) | Medicinal composition contg. total ginkgo flavone, its prepn. method and use | |
| CN100577165C (en) | Medicinal composition for treating cold wet numbness and preparation method thereof | |
| CN1771957A (en) | Bilobalide-containing medicine composition and its prepn and use | |
| CN1872051A (en) | Dry suspensoid of ginkgolide, and preparation method | |
| CN1899352A (en) | Chinese medicine effective part composition for supplementing qi and recovering pulse | |
| CN1454596A (en) | Compound medicine of ginkgo leaf extract and dipyridamole and preparing method thereof | |
| CN1895298A (en) | Medicinal preparation for treating and preventing coronary heart disease and thromboembolia disease and its preparation | |
| CN1939357A (en) | Preparation of Ginkgo Damo injection | |
| CN1616024A (en) | Shengmai powder injection and Shengmai chewable tablet and their production process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: DOBORIPHY PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: AERBERA MEDICINE (CHINA) CO., LTD. Effective date: 20080912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: No. 66, Xiangjiang Road, Meihekou, Jilin Patentee after: Aerbeila Medicine Holding (Tonghua) Co.,Ltd. Address before: Eastern section of North Ring Road, Meihekou, Jilin Patentee before: Aerbeila Pharmaceutical (China) Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: HU'NAN QIU ZEYOU PATENT STRATEGIC PLANNING CO., LT Free format text: FORMER OWNER: QIU ZEYOU Effective date: 20101028 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410011 28/F, SHUNTIANCHENG, NO.59, SECTION 2 OF FURONG MIDDLE ROAD, CHANGSHA CITY, HU'NAN PROVINCE TO: 410205 JUXING INDUSTRY BASE, NO.8, LUJING ROAD, CHANGSHA HIGH-TECH. DEVELOPMENT ZONE, YUELU DISTRICT, CHANGSHA CITY, HU'NAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101105 Address after: 135000 north section of Meihekou, Jilin, Zhujianglu Road Patentee after: WANSHENG LIANHE PHARMACEUTICAL Co.,Ltd. Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee before: Aerbeila Medicine Holding (Tonghua) Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: MEIHEKOU FENGSHUN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WINSUNNY UNION PHARMACEUTICAL CO., LTD. Effective date: 20110920 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110920 Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee after: Meihekou Feng Shun Pharmaceutical Co.,Ltd. Address before: 135000 north section of Meihekou, Jilin, Zhujianglu Road Patentee before: WANSHENG LIANHE PHARMACEUTICAL Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee |
Owner name: JILIN CHANGSHUN PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: MEIHEKOU FENGSHUN PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee after: JILIN CHANGSHUN PHARMACEUTICAL Co.,Ltd. Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee before: Meihekou Feng Shun Pharmaceutical Co.,Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee after: Hung Tai Pharmaceutical (China) Co.,Ltd. Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee before: JILIN CHANGSHUN PHARMACEUTICAL Co.,Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Jiang Yanyan Inventor after: Gong Jing Inventor after: Wang Jianhui Inventor before: Wang Jianhui |
|
| COR | Change of bibliographic data | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee after: HONGHE PHARMACEUTICAL CO.,LTD. Address before: 135000 No. 4655 Jianguo Road, Jilin, Meihekou Patentee before: Hung Tai Pharmaceutical (China) Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070613 |